Article

Transcript AA454543 Is a Novel Prognostic Marker for Hepatocellular Carcinoma after Curative Partial Hepatectomy

Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China.
Neoplasia (Impact Factor: 5.4). 02/2005; 7(2):91-8. DOI: 10.1593/neo.04472
Source: PubMed

ABSTRACT We have previously reported on the cDNA microarray gene expression profiles of hepatocellular carcinomas (HCCs). Among the genes that show prognostic significance and are overexpressed in tumor compared with adjacent nontumorous liver, transcript AA454543 may have potential for practical use. Our aim is to validate the prognostic significance of transcript AA454543 by alternative research methods and in a separate group of HCC patients.
The data of transcript AA454543 derived from microarray analysis of 48 patients having curative partial hepatectomy (group 1) were verified by quantitative reverse transcription polymerase chain reaction (r = 0.618, P < .001). A separate sample set of HCCs obtained from 53 patients (group 2) was examined and the association of AA454543 expression level with overall survival was again validated (P = .027). By Cox regression analysis, transcript AA454543 [hazard ratio (HR) = 3.0, P = .017] and pathologic tumor node metastasis (pTNM) stage (HR = 3.3, P = .010) were independent prognostic factors for overall survival. The accuracy of prediction for 3-year overall survival for transcript AA454543 (74.2%, P = .001) and pTNM stage (76.4%, P = .001) was comparable as measured by the area under the receiver operating characteristic curve.
Transcript AA454543 is potentially useful molecular prognostic marker for overall survival after curative partial hepatectomy for HCC.

0 Followers
 · 
94 Views
  • Source
    • "Such factors might be preoperatively determined tumor-related cell-free nucleic acids in plasma and serum. Recently, the preoperative plasma transcript AA454543 level has been identified as a prognostic parameter in hepatocellular carcinoma [6] [7]. However, such novel and promising prognostic markers are still based on the presence of tumor mass. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The GNAS1 locus encodes the Galphas protein, which stimulates the formation of cyclo-adenosinemonophosphate (cAMP). The cAMP pathway mediates pleiotropic effects, including the regulation of apoptosis and proliferation. We have recently shown that TT genotypes of the single-nucleotide polymorphism T393C in the gene GNAS1 predict the clinical outcome of patients with various carcinomas. Eighty-seven patients with intrahepatic cholangiocarcinoma (ICC) were retrospectively genotyped to elucidate a potential association between T393C genotypes and clinical outcome. ICCs of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate. Homozygous TT patients were at highest risk for cancer-related deaths (hazard ratio = 2.74; 95% confidence interval = 1.03-7.28) compared with C-allele carriers. Kaplan-Meier curves for disease-specific overall and local recurrence-free survival in a subgroup with R(0)-resected ICC showed a significant association of T393 homozygosity with outcome, which was confirmed in multivariate Cox regression analysis. GNAS1 T393C is a novel independent host factor for disease progression in patients with ICC. Our finding that TT homozygosity (and not CC homozygosity) was associated with unfavorable clinical outcome points to the complex and differing functional effects induced by GNAS1 T393C polymorphism in various human carcinomas.
    Neoplasia (New York, N.Y.) 03/2007; 9(2):159-65. DOI:10.1593/neo.06796 · 5.40 Impact Factor
  • Source
    • "Importantly, transcript AA45453 levels in tumor tissues and tumor stage were independent prognostic factors for overall survival [12]. The prognostic significance of transcript AA454543 was first identified in our earlier cDNA microarray dataset [11], in which data were validated by quantitative reverse transcription – polymerase chain reaction (RT-PCR) and then confirmed in a separate HCC sample set [12]. Thus, quantitative assay of the molecular marker transcript AA454543 in tumor tissues can provide general prognostic information (two independent cohorts of HCC patients, and prediction is independent of the assay method used). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously reported that tissue expression levels of transcript AA454543 in hepatocellular carcinoma (HCC) are significantly higher than those of normal livers, livers with cirrhosis, and livers with hepatitis. In addition, a higher level of transcript AA454543 in tumor tissues is associated with poor prognosis. We aim to examine whether quantitative measurement of preoperative plasma transcript AA454543 can provide similar prognostic information. Blood samples were obtained from 84 HCC patients before surgery. Real-time quantitative reverse transcription-polymerase chain reaction, using TaqMan system, was employed to measure plasma transcript AA454543 and alpha-fetoprotein (AFP) RNA levels. We assessed their prediction power in prognosis using univariate and multivariate analyses. High plasma transcript AA454543 RNA levels were associated with poor overall survival (log-rank test, P < .01). Patients with different plasma AFP RNA levels revealed no difference in overall survival (log-rank test, P = .88). By multivariate Cox regression analysis, plasma transcript AA454543 RNA level (hazard ratio = 4.8, P < .01) and tumor stage (hazard ratio = 1.7, P < .01) were determined to be independent risk factors for the prediction of overall survival. Preoperative plasma transcript AA454543 RNA level can provide prognostic information for HCC patients receiving curative partial hepatectomy.
    Neoplasia (New York, N.Y.) 10/2006; 8(9):696-701. DOI:10.1593/neo.06181 · 5.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This past year, we have seen a phenomenal growth in the number of articles submitted to Neoplasia, breaking all pre- vious records. While the number of submitted articles continues to rise on an annual basis, the editorial office con- tinues to maintain a very high standard of scientific quality, which has been consistently maintained over the last 7 years. Since its inception back in 1999, Neoplasia has been a trend-setting, broad-based cancer journal and was, in fact, the first journal to offer online web-based manuscript submission and peer review using our custom-designed ap- plication JournalSoft. Although the use of web-based manu- script processing is becoming more of a standard rather than the exception, the process utilized byNeoplasia offers many unique features, which were developed by scientists to facilitate the scientific process. One of these features, which authors who have had works published in Neoplasia are familiar with, is that, during the peer review process, Journal- Soft offers authors the ability to read reviewers' comments as they are submitted. This provides the authors with the opportunity to think about the comments and even begin to address the concerns prior to the receipt of additional reviewers' comments. JournalSoft also provides an oppor- tunity for the authors to reply to the anonymous reviewer(s) in a point-by-point fashion prior to editorial decision. This provides for a critical dialogue exchange, with the net benefit of improving the quality of the science and the speed of the review process. It is these types of innovations which make Neoplasia the first choice of a growing list of authors. During the past 3 years,Neoplasia has published consistent, broad-based articles from diverse areas of cancer research, as shown in Table 1. This table lists articles by general topic area for publication years 2003 -2005. Readily apparent from Table 1 is the fact that the number of articles in each category has been growing over the past 3 years. Moreover, the number of published articles increased by 21% in 2004 and increased again by 38% in 2005, revealing the rapid growth and impact Neoplasia has had in the research community. In the upcoming year (volume 8, 2006), we will be initiating a new open access policy for Neoplasia, wherein all published man- uscripts will be made rapidly available online for worldwide readership. This will provide authors the widest possible reader- ship, ensuring that articles published in Neoplasia will have the largest impact possible on the cancer research community. Neo- plasia is committed to meeting the changing concerns and needs of cancer investigators, and this is why we believe that open access for all published articles will be greatly beneficial.
    Neoplasia 01/2006; 7(12):1039-46. DOI:10.1593/neo.05793 · 5.40 Impact Factor
Show more

Preview

Download
2 Downloads
Available from